Loading...
LHCG logo

LHC Group, Inc.NasdaqGS:LHCG Aktierapport

Marknadsvärde US$5.3b
Aktiekurs
n/a
1Y32.1%
7D0.6%
1D0.5%
Portföljens värde
​
Utsikt

LHC Group, Inc.

NasdaqGS:LHCG Aktierapport

Börsvärde: US$5.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LHC Group (LHCG) Aktievy

LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. Mer information

LHCG fundamental analys
Snöflinga Score
Värdering0/6
Framtida tillväxt4/6
Tidigare resultat2/6
Finansiell hälsa2/6
Utdelningar0/6

Belöningar

Intäkterna förväntas växa med 37.23% per år

Riskanalys

Skuld täcks inte väl av operativt kassaflöde

Vinstmarginaler (1.7%) är lägre än förra året (5.2%)


LHCG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW493,174 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
493,174 investors already sharing narratives
View all narratives

LHC Group, Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för LHC Group
Historiska aktiekurser
Aktuell aktiekursUS$169.81
52 veckors högstaUS$169.84
52 veckors lägstaUS$115.32
Beta0.42
1 månads förändring3.76%
3 månaders förändring0.91%
1 års förändring32.12%
3 års förändring30.61%
5 års förändring178.06%
Förändring sedan börsintroduktionen893.04%

Senaste nyheter och uppdateringar

Recent updates

Seeking Alpha • Aug 03

LHC Group GAAP EPS of $0.35 misses by $0.95, revenue of $576.2M misses by $29.82M

LHC Group press release (NASDAQ:LHCG): Q2 GAAP EPS of $0.35 misses by $0.95. Revenue of $576.2M (+5.6% Y/Y) misses by $29.82M.
Seeking Alpha • Jul 19

LHC Group: UnitedHealth Merger Is Worth Playing

UnitedHealth’s ongoing acquisition of LHC Group is an interesting merger arbitrage setup, potentially offering an annualized return of 10%. The spread has recently widened as the transaction has attracted the FTC’s attention. The merger still seems likely to close - both companies have a low overlap, the home healthcare market is highly fragmented and the Humana-Kindred merger is a closely comparable transaction. The main risks are antitrust concerns over vertical integration and legal challenges to UnitedHealth’s ongoing merger with Change Healthcare. This is one of the ongoing large-cap merger arbitrage cases where the spread has recently widened. Healthcare and insurance giant UnitedHealth Group (UNH) is buying in-home healthcare company LHC Group (LHCG) at $170 per share. Board/shareholder approvals are already in-the-pocket. The only remaining hurdle is antitrust approval. Until recently, the market was not pricing in any regulatory risk as the spread was around 2%. In June, however, the merger received a second information request from the FTC. Since the news, the spread has jumped and is currently at 5%. In early July, rumors appeared that the FTC’s probe is focused on workers’ pay. Regulatory investigation is currently ongoing and the FTC will have 30 days to finish the review once the companies submit all the required information. Red dot represents FTC’s second request date. Yellow dot is where rumors appeared that FTC’s request is focused on labor pay. FTC’s inquiry comes in light of several industry developments. Firstly, UNH’s other ongoing $13bn merger with Change Healthcare (CHNG) has received pushback from the DoJ. The trial is set for August. However, CHNG operates in a different industry (medical billing software) than LHCG and the UHN-CHNG transaction has a much higher business overlap compared to UNH-LHCG merger. Secondly, since Joe Biden’s executive order on promoting competition in 2021, antitrust regulators have been putting increasing attention on healthcare mergers, highlighting impact on workers’ wages and the degree of vertical integration. These two concerns could be at play in the LHCG-UNH transaction. Also, as of May, the FTC has shifted to a majority-democratic commission, possibly pointing to tighter regulatory scrutiny. Despite these risks, I see several reasons why the LHCG merger is likely to receive regulatory clearance: UNH and LHCG have a low service overlap. The home healthcare market is highly fragmented. The Kindred-Humana merger is a comparable transaction in the home healthcare space. Recent FTC ruling history suggests that healthcare mergers are blocked due to geographical overlap/dominant market shares - largely not applicable to UNH-LHCG. Moreover, seemingly no mergers were blocked solely on labor pay grounds. Let’s go through these one-by-one. Limited Business Overlap LHCG operates in the post-acute healthcare market. The primary focus is on home-based healthcare services which have historically made a lion’s share of revenues at ~80%. This includes two reportable segments - home health (~70%) and home-/community-based care (~10%). The company operates home nursing agencies through which it provides post-acute nursing, medically-oriented social services and therapy. Other segments (~20% of revenues) are hospices, facility-based healthcare services and other healthcare businesses. Meanwhile, UNH is a vertically-integrated multinational company - it runs both health insurance (UnitedHealthcare) and health services (Optum) businesses. The Optum arm provides a continuum of healthcare services, including primary care, virtual care, behavioral health and ambulatory surgery. Even so, the company’s presence in the post-acute in-home care market has been limited. Apparently, ever since the pandemic, UNH has sought to expand the segment. Still, some overlap with LHCG remains - UNH launched its own service HouseCalls as well as acquired start-ups Landmark Health and naviHealth. HouseCalls in an annual in-home medical assessment and not a post-acute care service. Having said that, the number of patient visits in 2021 were at ~2.1m compared to 12m+ patient encounters at LHCG, though the latter include hospice patients. NaviHealth is a software business. The company operates a platform which helps hospital systems and healthcare providers manage clinical decision-making and track patient data. It should be noted that the focus is also on post-acute healthcare services. Landmark Health provides in-home care, however, the focus is exclusively on the sickest and most complicated patients. Services are offered in addition to regular primary care providers, such as LHCG. As of 2019, the number of annual visits was at 400k. Home-Care Market The in-home care market in the US is highly fragmented. To illustrate this, the largest market share captured by Kindred at Home (not publicly-listed) in recent years has been stable at only around 6% while other largest peers (Amedisys and Encompass) have occupied only ~4%-~5%. Company LHCG AMED EHC Kindred at Home Market Cap 5.0 4.1 4.9 Enterprise Value 5.8 4.5 8.0 FY2021 Home Care Revenues ($bn) 1.6 1.4 0.9 Market Share 4.4% 5.0% 3.9% 6.0% Sources: Company filings and HealthCare Appraisers. LexisNexis Visually, LHCG (top-right) appears to cover similar geographies as the largest peers Kindred, Amedisys and Encompass: AMED 8-K Filing, LHCG Investor Presentation, EHC Investor Reference Book, Kindred Healthcare Investor Presentation (Kindred acquired Gentiva in 2015) Looking more specifically, LHCG’s share of the number of home care agencies in several states is significant at ~70% in Mississippi and ~50% in Kentucky. However, these areas have relatively low numbers of total home care providers. Plus, total agency number includes only Medicare-registered providers whose count stands at ~11k compared to a rough estimate of ~35k+ including non-licensed agencies. With this in mind, the merger is unlikely to result in UNH obtaining any alarming market power other than in several specific geographies where divestitures, if needed, could be reasonable to expect. This makes any antitrust pushback very unlikely.
Seeking Alpha • Jul 06

FTC second request in LHC Group/UnitedHealth said to probe pay, labor market

The FTC's second request into UnitedHealth's (NYSE:UNH) planned $5.4 billion purchase of LHC Group (NASDAQ:LHCG) is said to be centered on workers' pay in the home healthcare space. The companies received a second request early last month that was unexpected, according to a Dealreporter item, which cited sources familiar. Kindred Healthcare's sale to Apollo Global also received a second request from the FTC. The FTC is said to be looking at how pay in the healthcare space and how minimum wage workers have trouble bargaining for higher wages, according to the report. UnitedHealth (UNG) agreed to buy home health business LHC Group for $170/share in late March.

Aktieägarnas avkastning

LHCGUS HealthcareUS Marknad
7D0.6%2.0%1.6%
1Y32.1%28.7%18.6%

Avkastning vs industri: LHCG översteg US Healthcare branschen som gav 28.7 % under det senaste året.

Avkastning vs Marknaden: LHCG översteg US marknaden som gav 18.6 % under det senaste året.

Prisvolatilitet

Is LHCG's price volatile compared to industry and market?
LHCG volatility
LHCG Average Weekly Movement2.1%
Healthcare Industry Average Movement7.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stabil aktiekurs: LHCG har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: LHCG s veckovolatilitet ( 2% ) har varit stabil under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
199423,000Keith Myerswww.lhcgroup.com

LHC Group, Inc. Sammanfattning av grunderna

Hur förhåller sig LHC Group:s resultat och omsättning till dess börsvärde?
LHCG grundläggande statistik
BörsvärdeUS$5.29b
Vinst(TTM)US$39.87m
Intäkter(TTM)US$2.28b
132.7x
P/E-förhållande
2.3x
P/S-förhållande

Är LHCG övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
LHCG resultaträkning (TTM)
IntäkterUS$2.28b
Kostnad för intäkterUS$1.40b
BruttovinstUS$883.61m
Övriga kostnaderUS$843.74m
IntäkterUS$39.87m

Senast redovisade vinst

Dec 31, 2022

Nästa vinstdatum

n/a

Vinst per aktie (EPS)1.28
Bruttomarginal38.71%
Nettovinstmarginal1.75%
Skuld/egenkapitalförhållande43.0%

Hur har LHCG utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/02/23 05:56
Aktiekurs vid dagens slut2023/02/21 00:00
Intäkter2022/12/31
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

LHC Group, Inc. bevakas av 20 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Matthew GillmorBaird
Steven ValiquetteBarclays
Sarah JamesBarclays